dMMR

About

Biomarker Type: Mismatch Repair

Present: True

Status: Deficient


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) dMMR Any solid tumor Pembrolizumab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab FDA
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel HC
Sensitivity (+) dMMR Endometrial Carcinoma Dostarlimab HC
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab HC
Sensitivity (+) dMMR Any solid tumor Pembrolizumab HC
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab FDA
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel FDA
Sensitivity (+) dMMR Endometrial Carcinoma Dostarlimab FDA
Sensitivity (+) dMMR Any solid tumor Dostarlimab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Nivolumab FDA
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel FDA